Rabinovich, N.R., McInnes, P., Klein, D.L., and Hall, B.F.: Vaccine technologies: view to the future. Science 1994, 265:1401–1404.
16-21 Most effective vaccines generate antibodies that prevent the damage caused by toxins or that neutralize the pathogen and stop infection.
Levine, M.M., and Levine, O.S.: Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use. Lancet 1997, 350:1386–1392.
Mouque, H., Scheid, J.F., Zoller, M.J., Krogsgaard, M., Ott, R.G., Shukair, S., Artyomov, M.N., Pietzsch, J., Connors, M., Pereyra, F., et al.: Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467:591–595.
Nichol, K.L., Lind, A., Margolis, K.L., Murdoch, M., McFadden, R., Hauge, M., Palese, P., and Garcia-Sastre, A.: Influenza vaccines: present and future. J. Clin. Invest. 2002, 110:9–13.
16-22 Effective vaccines must induce long-lasting protection while being safe and inexpensive.
Gupta, R.K., Best, J., and MacMahon, E.: Mumps and the UK epidemic 2005. BMJ 2005, 330:1132–1135.
Hviid, A., Rubin, S., and Mlemann, K.: Mumps. Lancet 2008, 371:932–944.
Magnan, S., and Drake, M.: The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 1995, 333:889–893.
16-23 Live-attenuated viral vaccines are usually more potent than ‘killed’ vaccines and can be made safer by the use of recombinant DNA technology.
Mueller, S.N., Langley, W.A., Carnero, E., García-Sastre, A., and Ahmed, R.: Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. J. Virol. 2010, 84:1847–1855.
Murphy, B.R., and Collins, P.L.: Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J. Clin. Invest. 2002, 110:21–27.
Pena, L., Vincent, A.L., Ye, J., Ciacci-Zanella, J.R., Angel, M., Lorusso, A., Gauger, P.C., Janke, B.H., Loving, C.L., and Perez, D.R.: Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses. J. Virol. 2011, 85:456–469.
Subbarao, K., Murphy, B.R., and Fauci, A.S.: Development of effective vaccines against pandemic influenza. Immunity 2006, 24:5–9.